Suppr超能文献

长效支气管扩张剂制剂(“奈沙普明多潘”)用于支气管痉挛性疾病的双盲试验。

Double-blind trial of a long-acting bronchodilator preparation ("Nethaprin Dospan") in bronchospastic disease.

作者信息

Kagan G, Rose R

出版信息

Curr Med Res Opin. 1976;4(6):436-41. doi: 10.1185/03007997609112000.

Abstract

A double-blind, placebo-controlled, crossover study was carried out in 48 patients with bronchospastic disease to assess the efficacy of a long-acting bronchodilator preparation ("Nethaprin Dospan") containing etafedrine hydrochloride, bufylline, doxylamine succinate and phenylephrine. Patients received 1 tablet nightly, with an extra dose in the morning if necessary, of active drug or placebo for 1 week, and were then crossed over to the alternative medication for a further week. All patients had marked disability, apparent on initial clinical examination and on respiratory function tests. The results showed that FEV1 and VC were significantly improved with the active medication, and patients slept better, had improved appetite and suppression of cough.

摘要

对48例支气管痉挛性疾病患者进行了一项双盲、安慰剂对照、交叉研究,以评估一种含有盐酸乙麻黄碱、丁菲林、琥珀酸多西拉敏和去氧肾上腺素的长效支气管扩张剂制剂(“Nethaprin Dospan”)的疗效。患者每晚服用1片活性药物或安慰剂,必要时早晨额外加服1剂,持续1周,然后交叉服用另一种药物再持续1周。所有患者在初次临床检查和呼吸功能测试中均表现出明显的功能障碍。结果显示,使用活性药物后,第1秒用力呼气容积(FEV1)和肺活量(VC)显著改善,患者睡眠更好、食欲改善且咳嗽得到抑制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验